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Purpose/Objective: To validate the 'mid-position' approach for lung 
tumor motion management in helical tomotherapy with 4D Monte 
Carlo planning simulation, in comparison with conventional ITV. 
Materials and Methods: 8 patients with stage I non-small cell lung 
cancer (NSCLC) treated by SBRT were included, as well as 6 patients 
with stage II-III NSCLC treated by Simultaneous Integrated Boost (SIB) 
and participating in a dose escalation protocol. Prior to treatment, a 
contrast-enhanced CT (CE-CT) and a 4DCT (for SBRT) or a combined 
4D FDG-PET-CT (for SIB) were acquired. The GTV, CTV, and OARs were 
delineated on the CE-CT according to our clinical protocol. Next, 4D 
data were used to generate first the ITV and then the MidP volume in 
its exact time-weighted mean position of the respiratory motion, using 
a validated Morphon non-rigid registration algorithm. The PTVs were 
finally drawn according to the margin formula for geometric 
uncertainties developed by Van Herk et al. and adapted to the 
specific features of lung tumor tomotherapy. For each patient, two 
treatments were planned based on margins derived from the ITV and 
MidP volume. Volumetric and dosimetric parameters, as well as 
conformity indexes were compared with both strategies. Moreover, 
dose distributions were computed using a 4D Monte Carlo (MC) model, 
in order to assess the impact of intra-fraction tumor motion on tumor 
coverage (quantified by D95), with and without the interplay effect. 
Results: For SBRT and SIB patients, the PTVs defined with the ITV 
approach were on average 1.2 times larger than those derived from 
MidP. Consequently, the dose to all the OARs was on average lower 
when using the MidP. Nonetheless, the planned dose conformity to 
TVs was identical between both strategies (0,92 ± 0,03 and 0,84 ± 
0,05 for DICE and Paddick indexes, respectively). For all SBRT 
patients, D95 to the GTV computed from 4D MC dose distributions 
complied within 1% of the planning recommendations when using the 
ITV approach. In contrast, MidP failed to ensure adequate GTV 
coverage in 3 patients. For one patient, the simulated interplay effect 
lowered the D95 to the GTV by 4.35% compared to the planned dose 
distribution (Fig a). Although the interplay effect did not affect the 
two other patients, simulated MC calculations demonstrated 
significant GTV underdosages, with D95 to GTV reduced by 2.16% and 
2.61% compared to the planned doses (Fig b). 4D MC computations are 
ongoing for the SIB group. 
 
  
Conclusions: Compared to the ITV, the MidP strategy significantly 
reduced the PTV and irradiated volumes in all patients. However, if 
MidP could safely be applied in helical tomotherapy in most cases, it 
might lead to insufficient tumor coverage for very small tumors (< 
5cc) with large motion (> 10mm). Those particular cases are indeed 
questioning the fundamental hypothesis underlying the framework of 
the MidP concept. As SIB treatments are usually delivered to large and 
centrally located tumors, MidP might allow for a safe reduction of the 
PTVs and irradiated tissues, although this still needs to be further 
confirmed.  
   
PO-0823   
Intensity modulated treatment plans reoptimization with 
megavoltage cone beam computed tomography dose 
L. Orlandini1, M. Betti1, T. Malatesta2, M. De Liguoro3, L. Cionini3 
1Centro Onccologico Fiorentino, Medical Physics, Firenze, Italy  
2FBF Isola Tiberina, Medical Physics, Roma, Italy  
3Centro Onccologico Fiorentino, Radiation Oncology, Firenze, Italy  
 
Purpose/Objective: The megavoltage cone beam computed 
tomography (MV-CBCT) dose may be considered in the treatment plan 
prescription dose specially for daily image guided radiation therapy 
(IGRT) treatments. The dosimetric differences on target volumes and 
organs at risks obtained optimizing the intensity modulated treatment 
plan (IMRT) with and without the MV-CBCT were investigated for 
clinical cases routinely treated. 
Materials and Methods: A Siemens Medical Solutions, an Artiste™ 
linear accelerators mounting a MV-CBCT device implemented in Philips 
Pinnacle3 Treatment Planning System (TPS) was used for this work. 
Two different type of treatment (head and neck and prostate) 
performed with daily IGRT-IMRT techniques were enrolled. Twenty 
prostate carcinomas and twelve head and neck tumors treatment 
planning were investigated. For each clinical case the dose 
distribution and the DVH due to IMRT alone (TP1), IMRT plus MV-CBCT 
dose (TP2), IMRT optimized including MV-CBCT dose (TP3) were 
examined. Dmean and Dmax were used for target volume comparison and 
dose volume histograms (DVHs) cut off points for organs at risks 
(OARs) comparison. The impact of the MV-CBCT protocol used on the 
integral dose defined as V5Gy was investigated. The CBCT dose 
calculated was assessed with ionization chamber measurements. 
Results: The theoretical treatment plan (TP1) compared with the one 
optimized with the MV CBCT dose (TP3) did not present difference on 
target dose coverage, while if compared with TP2 (treatment plan 
added with MV CBCT dose) a mean increase of 4,1% and 3% were 
obtained for Dmean and Dmax for ORL and prostate treatment 
respectively. The OARs sparing was worsened in both comparison also 
if a better sparing is obtained with TP2. For the parotides glands the 
Dmean percent difference ranged between +8% and 16 % and for the 
V40Gy of the rectum the percent difference was between 1.5 to 8%. 
The comparison between the 8 monitor units (MU) CBCT protocol 
routinely used and the 5 MU and 15 MU protocols showed and 
increased of the V5GY integral dose between 10 to 52 % and 20 to 66% 
for ORL and prostate treatment respectively. The decreased of V5GY 
integral dose obtained with the 5M CBCT protocol ranged between -2 
to –7% for for ORL and between -6 to –13% for prostate cases. 
Conclusions: Prostate and ORL treated with IMRT and IGRT techniques 
may not be performed without the use of the daily CBCT; it is 
therefore essential to integrate the MV-CBCT dose in the patient 
prescription.  
   
PO-0824   
Comparison of template-based Elekta VMAT plans with IMRT plans 
generated by the Varian planning system Eclipse 
S. Peters1, H. Schiefer1, M. Arn1, F. Herberth1, L. Plasswilm1 
1Kantonsspital St. Gallen, Klinik für Radio-Onkologie, St Gallen, 
Switzerland  
 
Purpose/Objective: VMAT is a complex, arc-based treatment 
technique for intensity modulated radiation therapy. For different 
treatment planning systems it has been shown that plan quality is 
comparable to fixed field IMRT. But achieving acceptable plan quality 
is often based on experience of the operator. This analysis compares 
the plan quality of template-based VMAT plans without operator 
interference against fixed field IMRT plans for Elekta linacs using the 
Varian TPS Eclipse on a statistical basis for various main tumour 
regions. 
Materials and Methods: 181 cases were selected for this study 
including 40 cervical and endometrial, 73 head and neck, 12 brain, 11 
breast and 45 prostate cancer cases. The IMRT plans were developed 
in clinical routine over the last three years using Eclipse TPS. VMAT 
plans were generated using a preclinical version of the Eclipse TPS 
including a VMAT optimizer for Elekta linacs. To standardize the 
optimizing process, tumour region specific optimizing templates were 
created. Based on these templates two VMAT plans were generated 
without interference of the operator: with one full arc (1A) and with 
two full arcs (2A), resp. one or two partial arcs for breast cancer 
cases. All plans were evaluated by target coverage, homogeneity and 
conformity; the organs at risk (OAR) were analysed according to plan 
objectives such as mean and maximum doses. If one or more 
objectives were exceeded, a second VMAT plan was created by 
adapting the optimizing constraints once. All evaluation parameters 
were averaged over all patients for each region and compared using 
the Wilcoxon matched-pair signed rank test. 
Results: For template-based 2A plans in 27 cases out of 181 an 
exceeding of the objectives for one or more OAR was found, in 13 
cases an over- or under-dosage in the PTV. For 1A plans 30 cases 
showed an exceeding of the OAR objectives, 25 for the target volume 
coverage. For the additionally modified plans the OAR exceeding was 
reduced to 23 cases for both 2A and 1A; the over- or under-dosage in 
the PTV was reduced to 8 cases for 2A and to 17 for 1A. In comparison 
to the IMRT plans the 1A and 2A plans showed good results concerning 
the target coverage. Small differences between the considered 
techniques can be found which depends on the tumour region. A 
similar behaviour was found for the OAR. But here, the differences 
between the different techniques and tumour regions show a wider 
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variation. Detailed values for the PTV and OAR can be found in table 
1. 
 
  
Conclusions: The Eclipse planning system is able to achieve a 
comparable plan quality for Elekta VMAT delivery technique to that of 
fixed field IMRT in terms of target coverage and critical structure 
sparing using optimizing templates without operator interference. 
Plans with 2 arcs show less exceeding of the objectives than plans 
with 1 arc. In the VMAT cases where the objectives are not met, 
adapting the optimizing parameters once results in an improvement of 
the target coverage and OAR sparing.  
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Purpose/Objective: Many indications suggest that a dose escalation in 
prostate carcinoma treatment could improve the disease local control. 
Several methods are developed to reduce the rectal volume involved 
in high doses since rectal toxicity is one of main aspects limiting the 
prescribed dose. One possible strategy is to insert between rectum 
and prostate walls a little balloon. This study aims to assess the 
efficacy of this experimental device in reducing rectal dose in 
prostate EBRT. 
Materials and Methods: 9 patients with prostate carcinoma were 
recruited in 2010 at the Oncology Institute of Veneto (Padova, Italy) 
for a 'one-arm' multicenter study to evaluate the use of a 
biodegradable implantable balloon in term of efficacy and safety. The 
balloon is made of co-polymer Poly(L-lactide-co-ε-caprolactone). After 
the implantation between prostate and rectum anterior wall the 
balloon is filled with physiological solution. It remains in situ at least 
the whole radiation treatment time. Every patient had a CT scan 
(CT1) before the implantation and one after (CT2). The last one was 
used for plan optimization. A mean of 4 CT scans were acquired for 
every patient during treatment to assess the stability of the device. 3 
treatment plans were calculated on CT1 and CT2:  
1. a 6 fields standard 3DCRT (the one actually delivered). 
2. a 7 fields 3DCRT technique. 
3. a 7 fields IMRT. 
The prescribed dose was D95=78 Gy in 39 fractions. D50, V75, V70, 
V65, V60, V50 and V78 rectum DVH points were evaluated. QUANTEC 
dose limits were also verified. 3DCRT plans calculated on CT2 were 
compared with the IMRT plans calculated on CT1 to evaluate the 
device efficacy instead a highly conformance technique. A t-test was 
used to evaluate the statistic significance between plans. 
Results: Dose analysis shows implant efficacy for both 6 and 7 fields 
3DCRT techniques. DVHs comparison shows a 40 % and 55% mean 
reduction in V50 and V60 values. D50 decreases from 54,95 Gy to 
44,26 Gy for the 6 fields 3DCRT with a reduction of 18% (p <= 0.01) 
and from 49.6 Gy to 38.8 Gy for the 7 fields 3DCRT with a reduction of 
21% (p <= 0.01). Balloon allows the right QUANTEC dose-volume 
constraints in 7 out of 9 patients. A significant reduction of V78 mean 
value is observed, passing from a 4.0 cc to 1.2 cc.  IMRT technique 
shows insignificant differences between cases. D50 is reduced of 3% 
while V78 remains about 1cc for both cases. QUANTEC limits are 
independently reached using IMRT. Dose comparison between 3DCRT 
techniques with balloon and IMRT technique without doesn’t show a 
clear advantage in using the experimental device. 
Conclusions: Our dosimetric study clearly shows the efficacy of the 
implantable device reducing rectal dose in case of 3DCRT techniques. 
IMRT technique with no device is comparable with the 3DCRT with 
device. 
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Purpose/Objective: To compare plan quality in terms of dosimetric 
homogeneity, target conformity, organ-at-risk (OAR) sparing, monitor 
unit (MU) usage, and beam-on time for eleven stereotactic 
radiosurgery patients using RapidArc™ volumetric- modulated 
arctherapy (VMAT) with both standard and flattening filter free 
modes. Plans where calculated with both a standard120 leaf MLC and 
a HD120 MLC. 
Materials and Methods: Eleven patients with one or more brain 
metastases underwent computed tomography simulation. Treatment 
planning was performed using Varian Eclipse ™ v10.0.39 to generate 
four 2-arc RapidArc plans.Each patient was planned with FFF and 
flattened mode with both a standard and high definition MLC. All 
plans were calculated to deliver the same mean dose tothe PTV. Plans 
were created with dose control tuning structures surrounding targets 
to maximize conformity and dose gradient. Dosimetric parameters 
used for target analysis were RTOG conformity index (CIRTOG), 
homogeneity index (HIRTOG), inverse Paddick Conformity Index(PCI) 
and D5–D95. OAR sparing was analyzed in terms of Dmax and D10cc for 
brain. Treatment delivery was evaluated based on measured beam-on 
times delivered on a Varian Truebeam, Varian Truebeam STx and 
Varian Clinac iX linear accelerators. 
Results: Dosimetric conformity, homogeneity, and OAR sparing were 
comparable when using the HDMLC irrespective of mode for all 
patients. The Paddick Conformity Index was inferior for the standard 
MLC plans than the HDMLC with the mean decreasing from 4.3(±1.2) 
to 3.8(± 0.7). The PTV homogeneity index was inferior for the 
standard MLC than the HDMLC plans, decreasing from 3.3(± 0.8) to 
2.4(± 0.7). Mean beam-on times for FFF mode and flattened mode 
were 3(±0.7) and 12(±2.4) minutes, respectively. Mean MUs were 6760 
and 7015, respectively.  
Conclusions: Dosimetric conformity, homogeneity, and OAR sparing 
were similar when planned with a HDMLC. There was some reduction 
in conformality when planned with a standard MLC. Conformality was 
independent of treatment mode. The use of FFF resulted in 
substantially less beam-on time and fewer MUs than standard mode. 
The rapid delivery of SRS with an HDMLC and FFF improved workflow 
on the linac and limited the potential for intra-fraction organ and 
patient motion, which can cause dosimetric errors  
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Purpose/Objective: It has previously been reported that VMAT 
reduces the overall treatment time for lung SABR compared to 
conformal therapy techniques. This study investigates whether the 
increased dose-rate available with Flattening-Filter Free (FFF) beams 
can be used to further decrease delivery times. An analysis was also 
made of FFF plan quality relative to standard (flattened-beam) plans. 
Materials and Methods: 5 patients were planned for lung SABR with a 
dose of 55Gy in 5 fractions. VMAT plans with flattened 6MV beams(6X) 
and flattening filter free (6XFFF) were compared. The 6XFFF beam 
energy was tuned so that dose was matched to the flattened 6X beam 
energy at a depth of 10cm in water. All planning was performed with 
Monaco v3.3*1 for delivery on a Synergy*1 Linac with AgilityTM head. An 
isocentre positioned at the patient mid-line was used for all plans. 
Treatment deliveries were verified using the Delta4*2 phantom and 
chamber measurements in a CIRS*3 lung phantom. Plans were 
compared in terms of measured delivery time, gamma index and PTV 
point dose. 
Results: Plans produced with both 6X and 6XFFF had comparable plan 
quality (Table 1) and were produced in a similar time-frame.The VMAT 
prescription class solution used clinically for 6X treatments did not 
require alteration when planned with 6XFFF. Dose deliveries for both 
